Case number 1:22-cv-00221
Otsuka Pharmaceutical Co., Ltd. et al v. Teva Pharmaceuticals USA, Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 27, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Leonard P. Stark of the United States Court of Appeals for the Federal Circuit. Please include the initials of the Judge (LPS) after the case number on all documents filed. (ntl) |
| Apr 27, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [10] Stipulated Consent Judgment and Injunction filed by Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S, ***Civil Case Terminated. Signed by Judge Leonard P. Stark on 4/27/22. (ntl) |
| Apr 27, 2022 | 11 | Patent/Trademark Report to Commissioner (4) Docket Text: Report to the Commissioner of Patents and Trademarks. (ntl) |
| Mar 25, 2022 | 10 | Proposed Consent Judgment (3) Docket Text: PROPOSED CONSENT JUDGMENT AND INJUNCTION (Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd.) by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Mayo, Andrew) |
| Mar 14, 2022 | N/A | Order (0) Docket Text: ORAL ORDER: Having reviewed the joint status report filed on March 9 (see, e.g., C.A. No. 22-221 D.I. 8), IT IS HEREBY ORDERED that the parties shall submit the following, to assist the Court in resolving their dispute as to the earliest date the FDA may approve any ANDAs (January 10, 2023 or December 27, 2024), which has implications for the timing of the trial, which will likely be rescheduled from its current dates of July and August 2022: (i) on March 23, the parties shall file simultaneous opening briefs, not to exceed 20 pages per side (i.e., 20 in total for plaintiffs and 20 in total for defendants), setting out the arguments for their position on the date the FDA may approve any ANDAs; (ii) on March 29, the parties shall file answering briefs, not to exceed 10 pages per side; and (iii) on March 31, the parties shall file reply briefs, not to exceed 5 pages per side. ORDERED by Judge Leonard P. Stark on 3/14/22. Associated Cases: 1:19-cv-01938-LPS, 1:22-cv-00221-LPS (ntl) |
| Mar 9, 2022 | 8 | Main Document (2) Docket Text: Joint STATUS REPORT by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # (1) Exhibit 1)(Mayo, Andrew) |
| Mar 9, 2022 | 8 | Exhibit 1 (7) |
| Feb 28, 2022 | N/A | Order (0) Docket Text: ORAL ORDER: IT IS HEREBY ORDERED that in anticipation of reassignment of these cases to another judge, the parties shall meet and confer and, no later than tomorrow, March 1, submit a joint status report (one that collectively addresses all of these related cases), advising the Court of the following (in addition to anything else the parties wish to report): (i) how many and which patents are at issue in any of these cases; (ii) how many applications or how many filers are at issue, in total, across these cases; (iii) how many contested infringement allegations remain to be litigated; (iv) how many invalidity issues are to be litigated; (v) when do any applicable stays (e.g., 30-month stay) expire; (vi) how long do the parties anticipate the upcoming bench trial to be; and (vii) how important is it that trial occur on or around July 25, 2022, as currently scheduled? ORDERED by Judge Leonard P. Stark on 2/28/22. Associated Cases: 1:19-cv-01938-LPS, 1:20-cv-01286-LPS, 1:20-cv-01763-LPS, 1:22-cv-00221-LPS (ntl) |
| Feb 23, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. (rjb) |
| Feb 22, 2022 | N/A | No Summons Issued (0) Docket Text: No Summons Issued. (nmg) |
| Feb 18, 2022 | 1 | Main Document (20) Docket Text: COMPLAINT for PATENT INFRINGEMENT filed against Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3807205.) - filed by Otsuka Pharmaceutical Co. and Ltd., H. Lundbeck A/S. (Attachments: # (1) Exhibit A-F, # (2) Civil Cover Sheet)(nmg) |
| Feb 18, 2022 | 1 | Exhibit A-F (232) |
| Feb 18, 2022 | 1 | Civil Cover Sheet (5) |
| Feb 18, 2022 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmg) |
| Feb 18, 2022 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 1/7/2022. Date of Expiration of Patent: See attached.Thirty Month Stay Deadline: 7/7/2024. (nmg) |
| Feb 18, 2022 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE48,059; 8,349,840; 8,618,109; 9,839,637; 10,307,419. (nmg) |
| Feb 18, 2022 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka Holdings Co., Ltd. for Otsuka Pharmaceutical Co., Ltd. filed by Otsuka Pharmaceutical Co., Ltd. (nmg) |
| Feb 18, 2022 | 6 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by H. Lundbeck A/S. (nmg) |
| Feb 18, 2022 | 1 | Complaint* (1) |
